Related Experiment Video
Updated: Jul 4, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Abciximab: a review and update for clinicians.
Ernest L Mazzaferri1, John J Young
1200 Davis Heart & Lung Research Institute, 473 W 12th Avenue, Columbus, OH 43210-1252, USA. ernest.mazzaferri@osumc.edu
Abciximab is a recommended glycoprotein (GP) IIb/IIIa inhibitor for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. It offers unique benefits like no renal dosing and reversible effects with platelet transfusions.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- The glycoprotein (GP) IIb/IIIa receptor is crucial in platelet aggregation and thrombus formation.
- GP IIb/IIIa inhibitors are vital for managing acute coronary syndromes and percutaneous coronary interventions.
- Abciximab is an established intravenous GP IIb/IIIa inhibitor with distinct characteristics.
Purpose of the Study:
- To highlight the role of GP IIb/IIIa receptors in thrombosis.
- To compare abciximab with other intravenous GP IIb/IIIa inhibitors.
- To emphasize abciximab's unique properties and guideline recommendations.
Main Methods:
- Review of current guidelines and clinical evidence.
- Comparative analysis of intravenous GP IIb/IIIa inhibitors.
- Focus on abciximab's pharmacological profile and clinical utility.
Main Results:
- Abciximab is highly recommended by major cardiology guidelines for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
- Abciximab demonstrates unique advantages, including the absence of a requirement for renal dose adjustment.
- The inhibitory effects of abciximab on platelet function are largely reversible through platelet transfusions.
Conclusions:
- Abciximab is a preferred GP IIb/IIIa inhibitor for specific high-risk cardiovascular interventions.
- Its favorable dosing profile and reversibility enhance its clinical applicability.
- Abciximab represents a dependable therapeutic option in interventional cardiology.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids